How Doctors Monitor Cancer Treatment Response: Imaging, Biomarkers, and Clinical Benefit

Assessing whether cancer treatment is working relies on multiple complementary measures. No single test tells the whole story.

Primary Response Metrics

• Tumor Size (RECIST 1.1): Target lesions measured on CT/MRI. Complete response (CR) = disappearance; Partial response (PR) = ≥30% decrease; Progressive disease (PD) = ≥20% increase; Stable disease (SD) = neither PR nor PD.
• Tumor Markers: PSA (prostate), CA-125 (ovarian), CEA (colorectal), CA 19-9 (pancreatic), AFP (hepatocellular). Trends matter more than single values; correlate with imaging.
• Functional Imaging: FDG-PET/CT for metabolic response (PERCIST); DOTATATE-PET for NETs; PSMA-PET for prostate cancer.
• Clinical Benefit: Symptom improvement (pain, dyspnea, obstruction), performance status, quality of life.
• Time-to-Event Endpoints: PFS (progression-free survival), TTF (time to treatment failure), OS (overall survival)—gold standard in trials.
• Overall Response Rate (ORR): CR + PR proportion; used in early-phase trials.

Integration in Practice

Multidisciplinary tumor boards synthesize imaging, labs, clinical exam, and patient-reported outcomes. Treatment continues if benefit > toxicity; switches at progression or intolerance. Liquid biopsy (ctDNA) is emerging for earlier detection of molecular progression.